Patent Application for Dichrostachys glomerata to Reduce Anxiety and Cravings

The USPTO has published a new patent application (US20260083792A1) for methods and compositions using Dichrostachys glomerata to reduce anxiety, stress, food cravings, and improve mood and overall health. The application was filed on September 25, 2024, by inventor Shil Kothari.

Patent Application: Dichrostachys glomerata Health Benefits

The USPTO has published a patent application (US20260083791A1) detailing methods and compositions using Dichrostachys glomerata for various health benefits, including reducing anxiety, food cravings, and stress, and improving mood and energy. The application was filed on September 25, 2024, by inventor Shil Kothari.

Formulation for Hair Growth

The USPTO has published a new patent application, US20260083789A1, for a formulation designed to stimulate hair growth and improve hair quality. The formulation primarily utilizes a nitrate-enriched extract of Amaranth, along with other plant-based ingredients. The application details the method of preparation and its potential use in enhancing hair growth rate, count, and density.

Antiviral Fungal Extracts Prevent Coronavirus Infections

The USPTO has published a patent application (US20260083788A1) detailing antiviral fungal extracts that may prevent coronavirus infections by interfering with the Spike protein. The application, filed by Mycotech Pharma AS, describes compositions derived from Agaricus blazei, Grifola frondosa, and Hericium erinaceus.

GABA-producing bacteria for improving health patent application

The USPTO has published a new patent application (US20260083786A1) detailing a composition comprising Lactobacillus brevis (NCIMB 41903) for use in regulating or treating metabolic diseases. The application was filed on September 17, 2025, by inventors Paul Ross and Catherine Stanton.

Patent Application: Bifidobacterium longum for Infant Infection Prevention

The USPTO has published a patent application (US20260083785A1) detailing the use of Bifidobacterium longum transitional microorganisms to prevent or reduce the risk of infection in infants and young children. The application was filed on September 27, 2023.

FDA Decision on Tradipitant New Drug Application Refusal

The Food and Drug Administration (FDA) has issued a final decision regarding the new drug application for Tradipitant. The agency has decided to refuse to approve the application, based on a proposal to do so. The specific details of the decision are confidential business information, but a redacted version is available.

FDA Variance Approval Letter to Dapper Rave, LLC

The Food and Drug Administration (FDA) has issued a variance approval letter to Dapper Rave, LLC, through its Center for Devices and Radiological Health (CDRH). This document signifies an approval for a specific variance requested by the company.

FDA Variance Approval Letter

The Food and Drug Administration (FDA) has issued a variance approval letter to Laina Callow. The letter, originating from the Center for Devices and Radiological Health (CDRH), indicates a specific approval related to a medical device or process. A redacted version is available for public review.

FDA Acknowledgment Letter to Axion Laser

The Food and Drug Administration (FDA) has issued an acknowledgment letter from its Division of Management and Budget (DMB) to Axion Laser. This notice confirms receipt of a submission, though no specific details about the submission's content or purpose are provided in the available information.